Basit öğe kaydını göster

Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line

dc.contributor.authorBostrom, Hans
dc.contributor.authorBaccarani, Michele
dc.contributor.authorCastagnetti, Fausto
dc.contributor.authorSimonsson, Bengt
dc.contributor.authorPorkka, Kimmo
dc.contributor.authorHAZNEDAROĞLU, İBRAHİM CELALETTİN
dc.contributor.authorNielsen, Johann Lanng
dc.contributor.authorHjorth-Hansen, Henrik
dc.contributor.authorWeis-Bjerrum, Ole
dc.contributor.authorTestoni, Nicoletta
dc.contributor.authorMartinelli, Giovanni
dc.contributor.authorPane, Fabrizio
dc.contributor.authorSaglio, Giuseppe
dc.contributor.authorRosti, Gianantonio
dc.contributor.authorNagler, Arnon
dc.contributor.authorPalandri, Francesca
dc.contributor.authorCambrin, Giovanna Rege
dc.contributor.authorLevato, Luciano
dc.contributor.authorPalmieri, Fausto
dc.contributor.authorAbruzzese, Elisabetta
dc.contributor.authorOezbek, Ugur
dc.contributor.authorKairisto, Veli
dc.date.accessioned2021-03-03T16:08:12Z
dc.date.available2021-03-03T16:08:12Z
dc.identifier.citationBaccarani M., Castagnetti F., Simonsson B., Porkka K., HAZNEDAROĞLU İ. C. , Nagler A., Palandri F., Cambrin G. R. , Levato L., Palmieri F., et al., "Cytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line", 50th Annual Meeting of the American-Society-of-Hematology, San-Francisco, Kostarika, 6 - 09 Aralık 2008, cilt.112, ss.75-76
dc.identifier.otherav_42a5431c-7639-43b3-8172-fdcb922c6eeb
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/48523
dc.language.isoeng
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectHematoloji
dc.subjectHEMATOLOJİ
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.titleCytogenetic and Molecular Response to Imatinib in High Risk (Sokal) Chronic Myeloid Leukemia (CML): Results of An European Leukemianet Prospective Study Comparing 400 Mg and 800 Mg Front-Line
dc.typeBildiri
dc.contributor.departmentUniversity of Bologna , ,
dc.identifier.volume112
dc.contributor.firstauthorID135484


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster